Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.

MLA

Tugal-Tutkun I, et al. “Efficacy of Infliximab in the Treatment of Uveitis That Is Resistant to Treatment with the Combination of Azathioprine, Cyclosporine, and Corticosteroids in Behçet’s Disease: An Open-Label Trial.” Arthritis & Rheumatism, vol. 52, no. 8, Aug. 2005, pp. 2478–84. EBSCOhost, https://doi.org/10.1002/art.21231.

APA

Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, & Gül A. (2005). Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis & Rheumatism, 52(8), 2478–2484. https://doi.org/10.1002/art.21231

Chicago

Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, and Gül A. 2005. “Efficacy of Infliximab in the Treatment of Uveitis That Is Resistant to Treatment with the Combination of Azathioprine, Cyclosporine, and Corticosteroids in Behçet’s Disease: An Open-Label Trial.” Arthritis & Rheumatism 52 (8): 2478–84. doi:10.1002/art.21231.